Review article · 2019 · Open access

Lurasidone compared to other atypical antipsychotic monotherapies for adolescent schizophrenia: a systematic literature review and network meta-analysis

Celso Arango, Daisy Ng‐Mak, Elaine Finn, Aidan Byrne, Antony D Loebel

European Child & Adolescent Psychiatry, 29(9), 1195–1205 · Published 22 November 2019 · DOI 10.1007/s00787-019-01425-2

Open PDFView at the publisherCite this paper

In brief

“Lurasidone compared to other atypical antipsychotic monotherapies for adolescent schizophrenia: a systematic literature review and network meta-analysis” is a 2019 review article by Celso Arango and 4 co-authors, published in European Child & Adolescent Psychiatry. OpenAlex counts 200 citations as of 20 November 2026, which puts it in the top 3% of works published in 2019 by citations. It is open access under a CC BY licence: the full text is free to read at European Child & Adolescent Psychiatry.

Citations
200
Most cited in
2020 (157)
Field-weighted impact
6.18
References
49
Authors
5

Abstract

This network meta-analysis assessed the efficacy and tolerability of lurasidone versus other oral atypical antipsychotic monotherapies in adolescent schizophrenia. A systematic literature review identified 13 randomized controlled trials of antipsychotics in adolescents with schizophrenia-spectrum disorders. A Bayesian network meta-analysis compared lurasidone to aripiprazole, asenapine, clozapine, olanzapine, paliperidone extended-release (ER), quetiapine, risperidone, and ziprasidone. Outcomes included Positive and Negative Syndrome Scale (PANSS), Clinical Global Impressions-Severity (CGI-S), weight gain, all-cause discontinuation, extrapyramidal symptoms (EPS), and akathisia. Results were reported as median differences for continuous outcomes and odds ratios (ORs) for binary outcomes, along with 95% credible intervals (95% CrI). Lurasidone was significantly more efficacious than placebo on the PANSS (- 7.95, 95% CrI - 11.76 to - 4.16) and CGI-S (- 0.44, 95% CrI - 0.67 to - 0.22) scores. Lurasidone was associated with similar weight gain to placebo and statistically significantly less weight gain versus olanzapine (- 3.62 kg, 95% CrI - 4.84 kg to - 2.41 kg), quetiapine (- 2.13 kg, 95% CrI - 3.20 kg to - 1.08 kg), risperidone (- 1.16 kg, 95% CrI - 2.14 kg to - 0.17 kg), asenapine (- 0.98 kg, 95% CrI - 1.71 kg to - 0.24 kg), and paliperidone ER (- 0.85 kg, 95% CrI - 1.57 kg to - 0.14 kg). The odds of all-cause discontinuation were significantly lower for lurasidone than aripiprazole (OR = 0.28, 95% CrI 0.10-0.76) and paliperidone ER (OR = 0.25, 95% CrI 0.08-0.81) and comparable to other antipsychotics. Rates of EPS and akathisia were similar for lurasidone and other atypical antipsychotics. In this network meta-analysis of atypical antipsychotics in adolescent schizophrenia, lurasidone was associated with similar efficacy, less weight gain, and lower risk of all-cause discontinuation compared to other oral atypical antipsychotics.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Arango, C., Ng‐Mak, D., Finn, E., Byrne, A., & Loebel, A. D. (2019). Lurasidone compared to other atypical antipsychotic monotherapies for adolescent schizophrenia: a systematic literature review and network meta-analysis. European Child & Adolescent Psychiatry, 29(9), 1195–1205. https://doi.org/10.1007/s00787-019-01425-2

MLA 9

Arango, Celso, et al. “Lurasidone compared to other atypical antipsychotic monotherapies for adolescent schizophrenia: a systematic literature review and network meta-analysis.” European Child & Adolescent Psychiatry, vol. 29, no. 9, 2019, pp. 1195–1205. https://doi.org/10.1007/s00787-019-01425-2.

Chicago

Arango, Celso, Daisy Ng‐Mak, Elaine Finn, Aidan Byrne, and Antony D Loebel. 2019. “Lurasidone compared to other atypical antipsychotic monotherapies for adolescent schizophrenia: a systematic literature review and network meta-analysis.” European Child & Adolescent Psychiatry 29 (9): 1195–1205. https://doi.org/10.1007/s00787-019-01425-2.

Harvard

Arango, C. et al. (2019) ‘Lurasidone compared to other atypical antipsychotic monotherapies for adolescent schizophrenia: a systematic literature review and network meta-analysis’, European Child & Adolescent Psychiatry, 29(9), pp. 1195–1205. doi:10.1007/s00787-019-01425-2.

IEEE

C. Arango, D. Ng‐Mak, E. Finn, A. Byrne, and A. D. Loebel, “Lurasidone compared to other atypical antipsychotic monotherapies for adolescent schizophrenia: a systematic literature review and network meta-analysis,” European Child & Adolescent Psychiatry, vol. 29, no. 9, pp. 1195–1205, 2019, doi: 10.1007/s00787-019-01425-2.

BibTeX

@article{arango2019lurasidone,
  title     = {{Lurasidone compared to other atypical antipsychotic monotherapies for adolescent schizophrenia: a systematic literature review and network meta-analysis}},
  author    = {Arango, Celso and Ng‐Mak, Daisy and Finn, Elaine and Byrne, Aidan and Loebel, Antony D},
  journal   = {European Child \& Adolescent Psychiatry},
  year      = {2019},
  volume    = {29},
  number    = {9},
  pages     = {1195--1205},
  doi       = {10.1007/s00787-019-01425-2},
  url       = {https://doi.org/10.1007/s00787-019-01425-2}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
2020157157
202177
202299
202388
202499
202566
202644

Its field-weighted citation impact is 6.18: it has been cited 6.18 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment

  • lurasidone
  • adolescent schizophrenia
  • atypical antipsychotics
  • monotherapy
  • aripiprazole
  • asenapine
  • clozapine
  • olanzapine

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Arango, C., Ng‐Mak, D., Finn, E., Byrne, A., & Loebel, A. D. (2019). Lurasidone compared to other atypical antipsychotic monotherapies for adolescent schizophrenia: a systematic literature review and network meta-analysis. European Child & Adolescent Psychiatry, 29(9), 1195–1205. https://doi.org/10.1007/s00787-019-01425-2

How many times has this paper been cited?

200 times, according to OpenAlex on 20 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at European Child & Adolescent Psychiatry: sign in and open the PDF from this page.

Who wrote this paper?

Celso Arango, Daisy Ng‐Mak, Elaine Finn, Aidan Byrne, Antony D Loebel.

What is the DOI of this paper?

10.1007/s00787-019-01425-2, permanently at https://doi.org/10.1007/s00787-019-01425-2. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 20 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.